Literature DB >> 11313768

Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome.

S M Houten1, J Koster, G J Romeijn, J Frenkel, M Di Rocco, U Caruso, P Landrieu, R I Kelley, W Kuis, B T Poll-The, K M Gibson, R J Wanders, H R Waterham.   

Abstract

Mevalonic aciduria (MA) and hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS) are two autosomal recessive inherited disorders both caused by a deficient activity of the enzyme mevalonate kinase (MK) resulting from mutations in the encoding MVK gene. Thus far, disease-causing mutations only could be detected by analysis of MVK cDNA. We now describe the genomic organization of the human MVK gene. It is 22 kb long and contains 11 exons of 46 to 837 bp and 10 introns of 379 bp to 4.2 kb. Three intron-exon boundaries were confirmed from natural splice variants, indicating the occurrence of exon skipping. Sequence analysis of 27 HIDS and MA patients confirmed all previously reported genotypes based on cDNA analysis and identified six novel nucleotide substitutions resulting in missense or nonsense mutations, providing new insights in the genotype/phenotype relation between HIDS and MA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313768     DOI: 10.1038/sj.ejhg.5200595

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  23 in total

1.  Sterol metabolism.

Authors:  Pierre Benveniste
Journal:  Arabidopsis Book       Date:  2002-03-27

2.  XOL-1, primary determinant of sexual fate in C. elegans, is a GHMP kinase family member and a structural prototype for a class of developmental regulators.

Authors:  John Gately Luz; Christian A Hassig; Catherine Pickle; Adam Godzik; Barbara J Meyer; Ian A Wilson
Journal:  Genes Dev       Date:  2003-04-02       Impact factor: 11.361

3.  Hyper-IgD and periodic fever syndrome (HIDS) due to compound heterozygosity for G336S and V377I in a 44-year-old patient with a 27-year history of fever.

Authors:  Stefan Schlabe; Carolynne Schwarze-Zander; Peter Lohse; Jürgen Kurt Rockstroh
Journal:  BMJ Case Rep       Date:  2016-11-29

4.  HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.

Authors:  Chi-Yi Yu; Elizabeth Theusch; Kathleen Lo; Lara M Mangravite; Devesh Naidoo; Mariya Kutilova; Marisa W Medina
Journal:  Hum Mol Genet       Date:  2013-09-02       Impact factor: 6.150

5.  Structural genomics of enzymes involved in sterol/isoprenoid biosynthesis.

Authors:  J B Bonanno; C Edo; N Eswar; U Pieper; M J Romanowski; V Ilyin; S E Gerchman; H Kycia; F W Studier; A Sali; S K Burley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 6.  Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer.

Authors:  Pinkal Desai; Allison Jay; Cathryn Bock; Gregory Dyson; Tochukwu Okwuosa; Michael S Simon
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

7.  Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept.

Authors:  P D Arkwright; M F McDermott; S M Houten; J Frenkel; H R Waterham; E Aganna; L J Hammond; R M Mirakian; P I Tomlin; P I Vijaydurai; A J Cant
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 8.  The role of HMGCR alternative splicing in statin efficacy.

Authors:  Marisa Wong Medina; Ronald M Krauss
Journal:  Trends Cardiovasc Med       Date:  2009-07       Impact factor: 6.677

Review 9.  Isoprenoids: remarkable diversity of form and function.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Lipids       Date:  2004-04       Impact factor: 1.880

10.  A monoallelic double mutation as a cause for TNF receptor-associated periodic fever syndrome.

Authors:  J Trübenbach; G Wildhardt; J Niebel; H Hawle; Daniela Steinberger
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.